Key Takeaways OM shares gain 14.3% after FDA 510(k) clearance for its next-generation Tablo hemodialysis system.OM's redesigned Tablo embeds cybersecurity across hardware, software and cloud.OM plans to ship the new Tablo in Q2 2026, with upgrade eligibility for existing customers.Outset Medical, Inc. (OM) recently announced that its next-generation Tablo hemodialysis system has received 510(k) clearance, marking a key regulatory milestone for the company. The clearance positions Tablo as the first dialysis ...